completed

Substantial reductions in cholesterol and blood pressure levels for an average of at least five years may lead to sustained long-term benefits, extending beyond the in-trial period, even without further treatments.

Participants enrolled in the clinical phase of HOPE-3 were followed passively (i.e. off study drug) after completion of the trial.

During the passive follow-up period, there were no protocol-mandated therapies and the primary care physicians will determine treatment of all study participants based on their interpretation of the available evidence.

Primary endpoint:

Occurrence of major CV events

Study Type

Observational

Study Design

Follow-up will conducted yearly by direct or telephone contact

NO. of Countries

18

NO. of Sites

177

NO. of Participants

10257

Study Period

2016-2019

Sponsor

PHRI

Back To Top